Abstract
Summary: Because diabetes mellitus is still one of the diseases that cannot be cured but can be successfully compensated, the age of the patients we need to care for is increasing. Even with increasing comorbidities and also with what we call a fragile patient.
Experience shows that the vast majority of large cardiovascular safety studies of antidiabetics were performed on the population under the age of 65, ie at the time of their conclusion, the participants were around 70 years old. And the median of our diabetic population is around these 70 years.
At the same time, we can say with a bit of exaggeration that we do not actually know how to treat elderly patients with diabetes so that the treatment is cardiovascularly safe. That is why we should also start using the term gerontodiabetology - not to create a new independent field, but with a clear understanding of what it contains.
